Sacramento, California | February 19, 2026 — KilgourMD announced results from an independent Phase II clinical trial evaluating its menopause-focused hair restoration platform, demonstrating clinically meaningful regrowth and reduced shedding in women experiencing androgenetic alopecia. The four-month study assessed the company’s Prevention and Treatment Serums in 43 menopausal-aged participants with clinically significant hair loss. Findings revealed measurable follicular recovery and visible density improvements, positioning the system as a scientifically validated intervention for a historically underserved patient population.
Science Significance
The trial represents one of the first structured clinical evaluations specifically targeting menopause-associated androgenetic alopecia, a condition driven by hormonal decline, follicular miniaturization, and scalp aging. By day 120, 53% of participants achieved at least a half-grade improvement on the modified Female Ludwig scale, while 26% demonstrated a full one-grade improvement, reflecting clinically meaningful regrowth. Across the cohort, an average 11.1% improvement in Ludwig score was recorded within four months. The system also produced a 60% reduction in hair shedding, with measurable decreases observed as early as day 45. Dermatologist-graded imaging confirmed enhanced scalp coverage, while standardized wash and comb testing validated normalization of the hair growth cycle. These outcomes suggest the formulation may influence follicular health, anagen phase duration, and scalp microenvironment optimization.
Regulatory Significance
While positioned within the dermo-cosmetic category, the use of Phase II clinical methodology, dermatologist evaluation, and objective imaging endpoints elevates the system’s scientific credibility. Trials employing medical grading scales and independent physician review reflect clinical research rigor more commonly associated with therapeutic product development. Should further studies validate efficacy and safety, the platform could potentially pursue regulated therapeutic positioning, bridging the gap between cosmetic scalp care and medically guided hair restoration science.
Business Significance
Advertisement
From a commercial perspective, the validated results establish KilgourMD as a science-driven entrant in the global hair loss market. Menopause-related hair thinning represents a rapidly expanding segment within dermatology and women’s health. Demonstrating clinically proven regrowth within four months differentiates the brand from perception-based cosmetic competitors. The findings also support premium product positioning, physician channel expansion, and dermatology clinic partnerships. Peer-review publication of the trial data, currently underway, may further enhance credibility and market adoption.
Patients’ Significance
Hair loss during menopause is often associated with psychological distress, reduced self-confidence, and diminished quality of life. Traditional pharmaceutical options may carry side effects or inconsistent efficacy in post-menopausal populations. A clinically validated system designed specifically for this demographic offers a targeted alternative. Participants reported visible density improvements and healthier scalp appearance, reinforcing the objective findings. For women historically excluded from hair loss trials, the study represents progress toward inclusive dermatologic innovation.
Policy Significance
The trial highlights broader healthcare equity considerations in dermatology research. Menopausal women have been underrepresented in hair loss clinical studies despite experiencing significant alopecia burden. Increased investment in gender-specific dermatologic research, hormone-related follicular biology, and aging scalp science aligns with emerging policy priorities focused on women’s health innovation. Evidence-based cosmetic and therapeutic crossover products may also influence future regulatory frameworks governing clinically validated aesthetic treatments.
KilgourMD’s Phase II findings mark an important advancement in menopause-focused hair restoration science. By demonstrating measurable regrowth, reduced shedding, and dermatologist-validated outcomes within a four-month period, the system establishes a new benchmark for evidence-based scalp health interventions. As peer review progresses and further trials expand validation, menopause-targeted hair loss solutions may move closer to mainstream clinical and dermatologic adoption.
Source: KilgourMD press release
